AAPL   396.25 (+3.28%)
MSFT   214.77 (+0.51%)
FB   248.04 (+1.21%)
GOOGL   1,564.49 (+1.66%)
AMZN   3,292.71 (+2.90%)
NVDA   423.93 (+1.14%)
CGC   18.07 (+3.73%)
BABA   258.55 (-0.94%)
MU   50.94 (+0.47%)
TSLA   1,698.58 (+9.97%)
T   29.92 (-0.70%)
DIS   119.90 (+0.47%)
NFLX   563.66 (+2.72%)
BAC   24.31 (+1.21%)
BA   181.75 (+1.85%)
AAPL   396.25 (+3.28%)
MSFT   214.77 (+0.51%)
FB   248.04 (+1.21%)
GOOGL   1,564.49 (+1.66%)
AMZN   3,292.71 (+2.90%)
NVDA   423.93 (+1.14%)
CGC   18.07 (+3.73%)
BABA   258.55 (-0.94%)
MU   50.94 (+0.47%)
TSLA   1,698.58 (+9.97%)
T   29.92 (-0.70%)
DIS   119.90 (+0.47%)
NFLX   563.66 (+2.72%)
BAC   24.31 (+1.21%)
BA   181.75 (+1.85%)
AAPL   396.25 (+3.28%)
MSFT   214.77 (+0.51%)
FB   248.04 (+1.21%)
GOOGL   1,564.49 (+1.66%)
AMZN   3,292.71 (+2.90%)
NVDA   423.93 (+1.14%)
CGC   18.07 (+3.73%)
BABA   258.55 (-0.94%)
MU   50.94 (+0.47%)
TSLA   1,698.58 (+9.97%)
T   29.92 (-0.70%)
DIS   119.90 (+0.47%)
NFLX   563.66 (+2.72%)
BAC   24.31 (+1.21%)
BA   181.75 (+1.85%)
AAPL   396.25 (+3.28%)
MSFT   214.77 (+0.51%)
FB   248.04 (+1.21%)
GOOGL   1,564.49 (+1.66%)
AMZN   3,292.71 (+2.90%)
NVDA   423.93 (+1.14%)
CGC   18.07 (+3.73%)
BABA   258.55 (-0.94%)
MU   50.94 (+0.47%)
TSLA   1,698.58 (+9.97%)
T   29.92 (-0.70%)
DIS   119.90 (+0.47%)
NFLX   563.66 (+2.72%)
BAC   24.31 (+1.21%)
BA   181.75 (+1.85%)
Log in

OTCMKTS:NXNNNexeon Medsystems Stock Price, Forecast & News

$0.0080
0.00 (0.00 %)
(As of 07/13/2020 01:29 PM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.15
$0.30
52-Week Range
$0.00
Now: $0.01
$4.50
VolumeN/A
Average Volume2,374 shs
Market Capitalization$16,320.00
P/E RatioN/A
Dividend YieldN/A
Beta2.33
Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.
Read More
Nexeon Medsystems logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.76 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NXNN
CUSIPN/A
CIKN/A
Phone844-919-9990

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.30 million

Profitability

Miscellaneous

Employees62
Market Cap$16,320.00
Next Earnings DateN/A
OptionableNot Optionable

Receive NXNN News and Ratings via Email

Sign-up to receive the latest news and ratings for NXNN and its competitors with MarketBeat's FREE daily newsletter.

Nexeon Medsystems (OTCMKTS:NXNN) Frequently Asked Questions

How has Nexeon Medsystems' stock been impacted by COVID-19 (Coronavirus)?

Nexeon Medsystems' stock was trading at $0.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NXNN stock has decreased by 98.4% and is now trading at $0.0080. View which stocks have been most impacted by Coronavirus.

How were Nexeon Medsystems' earnings last quarter?

Nexeon Medsystems Inc (OTCMKTS:NXNN) released its earnings results on Monday, May, 21st. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. The business earned $2.87 million during the quarter, compared to analysts' expectations of $1.70 million. View Nexeon Medsystems' earnings history.

Has Nexeon Medsystems been receiving favorable news coverage?

News coverage about NXNN stock has been trending very negative this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nexeon Medsystems earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Nexeon Medsystems.

Who are some of Nexeon Medsystems' key competitors?

What other stocks do shareholders of Nexeon Medsystems own?

Who are Nexeon Medsystems' key executives?

Nexeon Medsystems' management team includes the following people:
  • Mr. William Rosellini M.B.A., J.D., MBA, Chairman & CEO (Age 39)
  • Mr. Christopher R. Miller, Chief Financial Officer (Age 49)
  • Mr. Cathal Mc Fadden, VP of Operations
  • Dr. Austin Duke Ph.D., Chief Science Officer

What is Nexeon Medsystems' stock symbol?

Nexeon Medsystems trades on the OTCMKTS under the ticker symbol "NXNN."

How do I buy shares of Nexeon Medsystems?

Shares of NXNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nexeon Medsystems' stock price today?

One share of NXNN stock can currently be purchased for approximately $0.01.

How big of a company is Nexeon Medsystems?

Nexeon Medsystems has a market capitalization of $16,320.00 and generates $3.30 million in revenue each year. Nexeon Medsystems employs 62 workers across the globe.

What is Nexeon Medsystems' official website?

The official website for Nexeon Medsystems is www.nexeonmed.com.

How can I contact Nexeon Medsystems?

Nexeon Medsystems' mailing address is 1910 PACIFIC AVENUE SUITE 20000, DALLAS TX, 75201. The company can be reached via phone at 844-919-9990 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.